News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
295,478 Results
Type
Article (10913)
Company Profile (62)
Press Release (284503)
Section
Business (99854)
Career Advice (685)
Deals (17838)
Drug Delivery (13)
Drug Development (30887)
Employer Resources (40)
FDA (6725)
Job Trends (6360)
News (155975)
Policy (11087)
Tag
Academia (791)
Allergies (57)
Alliances (20654)
Alzheimer's disease (433)
Approvals (6754)
Artificial intelligence (57)
Bankruptcy (112)
Best Places to Work (5197)
Biotechnology (59)
Breast cancer (93)
Cancer (588)
Career advice (587)
Cell therapy (112)
Clinical research (25202)
Collaboration (218)
Compensation (105)
COVID-19 (783)
C-suite (72)
Data (665)
Diabetes (58)
Diagnostics (2835)
Earnings (43886)
Events (47291)
Executive appointments (219)
FDA (7018)
Funding (193)
Gene therapy (53)
GLP-1 (166)
Government (982)
Healthcare (6846)
Infectious disease (811)
Inflammatory bowel disease (47)
Interviews (85)
IPO (8896)
Job creations (1401)
Job search strategy (534)
Layoffs (119)
Legal (2912)
Lung cancer (62)
Lymphoma (47)
Manufacturing (63)
Medical device (4574)
Medtech (4576)
Mergers & acquisitions (9062)
Metabolic disorders (146)
Neuroscience (561)
NextGen Class of 2024 (2234)
Non-profit (1169)
Northern California (840)
Obesity (71)
Opinion (51)
Peanut (44)
People (30934)
Phase I (7258)
Phase II (10457)
Phase III (9223)
Pipeline (326)
Postmarket research (1172)
Preclinical (3124)
Press Release (69)
Radiopharmaceuticals (131)
Rare diseases (90)
Real estate (2321)
Regulatory (7695)
Research institute (816)
Resumes & cover letters (90)
Southern California (698)
Startups (1518)
United States (6896)
Vaccines (126)
Date
Today (63)
Last 7 days (273)
Last 30 days (1092)
Last 365 days (16340)
2024 (16278)
2023 (19053)
2022 (25523)
2021 (27303)
2020 (24467)
2019 (18269)
2018 (13842)
2017 (13863)
2016 (12854)
2015 (16263)
2014 (12488)
2013 (9951)
2012 (10657)
2011 (11230)
2010 (10678)
Location
Africa (272)
Arizona (68)
Asia (15105)
Australia (2160)
California (1806)
Canada (851)
China (82)
Colorado (65)
Connecticut (86)
Delaware (44)
Europe (33821)
Florida (192)
Illinois (125)
Indiana (93)
Japan (58)
Maryland (245)
Massachusetts (1469)
Michigan (93)
Minnesota (117)
New Jersey (650)
New York (475)
North Carolina (341)
Northern California (840)
Ohio (67)
Pennsylvania (336)
South America (409)
Southern California (698)
Texas (219)
Utah (47)
Washington State (173)
295,478 Results for "reaction biology corp".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Reaction Biology Launches Innovative Offering Within Its Kinase Testing Platform and Presents New Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Reaction Biology (“Reaction” or the “Company”), an industry-leading provider of drug discovery and development services, today announced that it will feature its recently launched HotSpot™ ATP-Max KinomeScreen at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 7-10, 2024, in San Diego, California.
April 3, 2024
·
6 min read
Approvals
ARS Pharma Gets FDA Green Light for First Nasal Spray for Severe Allergic Reactions
ARS Pharma’s neffy on Friday became the first FDA-approved nasal spray to address severe allergic reactions, including those that might lead to life-threatening anaphylaxis.
August 12, 2024
·
2 min read
·
Tristan Manalac
Biotech Bay
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology
Cytokinetics, Incorporated announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscle Biology Research Symposium , May 17th, 2024 at the Mission Bay Conference Center in San Francisco.
May 17, 2024
·
5 min read
Policy
ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
ARS Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion on the application for marketing authorization for EURneffy® and recommended related market authorization in the European Union for the emergency treatment of allergic reactions.
June 28, 2024
·
6 min read
Pharm Country
New York’s Only Outpatient Program for Reducing Allergic Reactions to Cancer Treatments Hits New Care Milestone
Approximately 10% of people diagnosed with cancer experience hypersensitivity reactions to certain therapies—which range from a mild skin rash to anaphylaxis —even when they were pretreated with antihistamines and steroids.
May 20, 2024
·
4 min read
UniDoc Health Corp. Reflects on a Year of Growth and Innovation
December 17, 2024
·
7 min read
Drug Development
Tonix Pharmaceuticals Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Reaction and Prevention of PTSD
Tonix Pharmaceuticals Holding Corp. today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the Phase 2 investigator-initiated OASIS trial to evaluate TNX-102 SL1 in reducing the severity of acute stress reaction (ASR) and the frequency of acute stress disorder (ASD) and posttraumatic stress disorder (PTSD).
February 12, 2024
·
10 min read
Press Releases
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
November 11, 2024
·
8 min read
Press Releases
Sharp Therapeutics Corp. Announces Completion of Qualifying Transaction
December 12, 2024
·
9 min read
Protect Pharmaceutical Corp. Issues Corporate Update
Protect Pharmaceutical Corp.'s (OTC: PRTT) (“Company”) President, Ali Yildiz, provides its shareholders with the following informational update: “July 1, 2024 Dear Shareholders: The Company’s PCAOB audit for the fiscal year of 2023 is near completion.
July 1, 2024
·
4 min read
1 of 29,548
Next